PRIMA-1 synergizes with adriamycin to induce cell death in non-small cell lung cancer cells

Journal of Cellular Biochemistry

Volumn 104, Issue 6, 2008, Pages 2363-2373

  Magrini, R ^a,b   Russo, D ^a   Ottaggio, L ^a   Fronza, G ^a   Inga, A ^a   Menichini, P ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b Siena Biotech SpA   (Italy)

Author keywords

Apoptosis; Cytotoxicity; Non small cell lung cancer; p53; PRIMA 1

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; PRIMA 1; PROTEIN P53;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN DEGRADATION; STATISTICAL SIGNIFICANCE;

APOPTOSIS REGULATORY PROTEINS; AZA COMPOUNDS; BICYCLO COMPOUNDS, HETEROCYCLIC; CARCINOMA, NON-SMALL-CELL LUNG; CELL DEATH; CELL LINE, TUMOR; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA FRAGMENTATION; DOXORUBICIN; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; HUMANS; LUNG NEOPLASMS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53; ULTRAVIOLET RAYS;

EID: 49049096115     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.21794     Document Type: Article

References (43)

1. Bossi G, Lapi E, Strano S, Rinaldo C, Blandino G, Sacchi A. 2006. Mutant p53 gain of function: Reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression. Oncogene 25:304-309.
2. Bykov VJ, Issaeva N, Selivanova G, Wiman KG. 2002a. Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: A statistical analysis of information in the National Cancer Institute database. Carcinogenesis 23:2011-2018.
3. Bykov VJ, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P, Bergman J, Wiman KG, Selivanova G. 2002b. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med 8:282-288.
4. Bykov VJ, Issaeva N, Zache N, Shilov A, Hultcrantz M, Bergman J, Selivanova G, Wiman KG. 2005a. Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs. J Biol Chem 280:30384-30391.
5. Bykov VJ, Zache N, Stridh H, Westman J, Bergman J, Selivanova G, Wiman KG. 2005b. PRIMA-1(MET) synergizes with cisplatin to induce tumor cell apoptosis. Oncogene 24:3484-3491.
6. Chipuk JE, Green DR. 2005. Do inducers of apoptosis trigger caspase-independent cell death? Nat Rev Mol Cell Biol 6:268-275.
7. Chipuk JE, Green DR. 2006. Dissecting p53-dependent apoptosis. Cell Death Differ 13:994-1002.
8. Chipuk JE, Maurer U, Green DR, Schuler M. 2003. Pharmacologic activation of p53 elicits Bax-dependent apoptosis in the absence of transcription. Cancer Cell 4:371-381.
9. Chipuk JE, Kuwana T, Bouchier-Hayes L, Droin NM, Newmeyer DD, Schuler M, Green DR. 2004. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 303:1010-1014.
10. Chipuk JE, Bouchier-Hayes L, Kuwana T, Newmeyer DD, Green DR. 2005. PUMA couples the nuclear and cytoplasmic proapoptotic function of p53. Science 309:1732-1735.
11. Coultas L, Strasser A. 2000. The molecular control of DNA damage-induced cell death. Apoptosis 5:491-507.
12. Crighton D, Ryan KM. 2004. Splicing DNA-damage responses to tumour cell death. Biochim Biophys Acta 1705:3-15.
13. Deb S, Jackson CT, Subler MA, Martin DW. 1992. Modulation of cellular and viral promoters by mutant human p53 proteins found in tumor cells. J Virol 66:6164-6170.
14. Dittmer D, Pati S, Zambetti G, Chu S, Teresky AK, Moore M, Finlay C, Levine AJ. 1993. Gain of function mutations in p53. Nat Genet 4:42-46.
15. Fennell DA. 2005. Caspase regulation in non-small cell lung cancer and its potential for therapeutic exploitation. Clin Cancer Res 11:2097-2105.
16. Fesik SW. 2005. Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer 5:876-885.
17. Hall PA, McCluggage WG. 2006. Assessing p53 in clinical contexts: Unlearned lessons and new perspectives. J Pathol 208:1-6.
18. Haura EB, Cress WD, Chellappan S, Zheng Z, Bepler G. 2004. Antiapoptotic signaling pathways in non-small-cell lung cancer: Biology and therapeutic strategies. Clin Lung Cancer 6:113-122.
19. Horn HF, Vousden KH. 2007. Coping with stress: Multiple ways to activate p53. Oncogene 26:1306-1316.
20. Issaeva N, Friedler A, Bozko P, Wiman KG, Fersht AR, Selivanova G. 2003. Rescue of mutants of the tumor suppressor p53 in cancer cells by a designed peptide. Proc Natl Acad Sci USA 100:13303-13307.
21. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ. 2005. Cancer statistics. CA Cancer J Clin 55:10-30.
22. Joseph B, Ekedahl J, Lewensohn R, Marchetti P, Formstecher P, Zhivotovsky B. 2001. Defective caspase-3 relocalization in non-small cell lung carcinoma. Oncogene 20:2877-2888.
23. Kaufmann SH, Vaux DL. 2003. Alterations in the apoptotic machinery and their potential role in anticancer drug resistance. Oncogene 22:7414-7430.
24. Levine AJ. 1997. p53, the cellular gatekeeper for growth and division. Cell 88:323-331.
25. Li Y, Mao Y, Brandt-Rauf PW, Williams AC, Fine RL. 2005. Selective induction of apoptosis in mutant p53 premalignant and malignant cancer cells by PRIMA-1 through the c-Jun-NH2-kinase pathway. Mol Cancer Ther 4:901-909.
26. Loprevite M, Varesco L, Favoni R, Ferrara GBS, Moro F, Ottaggio L, Fronza G, Campomenosi P, Abbondandolo A, Cutrona G, Roncella S, Albini A, Aluigi MG, Pozzi S, Pera C, Biticchi R, Gismondi V, Grossi F, Pennucci MC, Ardizzoni A. 1997. Analysis of K-ras, p53, bcl-2 and Rb expression in non-small cell lung cancer cell lines. Int J Oncol 11:1203-1208.
27. Magrini R, Russo D, Fronza G, Inga A, Menichini P. 2007. The kinetics of p53-binding and histone acetylation at target promoters do not strictly correlate with gene expression after UV damage. J Cell Biochem 100:1276-1287.
28. Norbury CJ, Zhivotovsky B. 2004. DNA damage-induced apoptosis. Oncogene 23:2797-2808.
29. North S, Pluquet O, Maurici D, El-Ghissassi F, Hainaut P. 2002. Restoration of wild-type conformation and activity of a temperature-sensitive mutant of p53 (p53(V272M)) by the cytoprotective aminothiol WR1065 in the esophageal cancer cell line TE-2. Mol Carcinog 33:181-188.
30. Peng Y, Li C, Chen L, Sebti S, Chen J. 2003. Rescue of mutant p53 transcription function by ellipticine. Oncogene 22:4478-4487.
31. Rehman A, Chahal MS, Tang X, Bruce JE, Pommier Y, Daoud SS. 2005. Proteomic identification of heat shock protein 90 as a candidate target for p53 mutation reactivation by PRIMA-1 in breast cancer cells. Breast Cancer Res 7:R765-R774.
32. Rokaeus N, Klein G, Wiman KG, Szekely L, Mattsson K. 2007. PRIMA-1(MET) induces nucleolar accumulation of mutant p53 and PML nuclear body-associated proteins. Oncogene 26:982-992.
33. Scian MJ, Stagliano KE, Deb D, Ellis MA, Carchman EH, Das A, Valerie K, Deb SP, Deb S. 2004. Tumor-derived p53 mutants induce oncogenesis by transactivating growth-promoting genes. Oncogene 23:4430-4443.
34. Selivanova G, Wiman KG. 2007. Reactivation of mutant p53: Molecular mechanisms and therapeutic potential. Oncogene 26:2243-2254.
35. Shi H, Lambert J, Hautefeuille A, Bykov V, Wiman K, Hainaut P, Caron de Fromentel C. 2007. In vitro and in vivo cytotoxic effects of PRIMA-1 on Hepatocellular Carcinoma cells expressing mutant p53ser249. Carcinogenesis DOI: 10.1093/carcin/bgm 266.
36. Sigal A, Rotter V. 2000. Oncogenic mutations of the p53 tumor suppressor: The demons of the guardian of the genome. Cancer Res 60:6788-6793.
37. Soussi T, Lozano G. 2005. p53 mutation heterogeneity in cancer. Biochem Biophys Res Commun 331:834-842.
38. Spira A, Ettinger DS. 2004. Multidisciplinary management of lung cancer. N Engl J Med 350:379-392.
39. Takimoto R, Wang W, Dicker DT, Rastinejad F, Lyssikatos J, el-Deiry WS. 2002. The mutant p53-conformation modifying drug, CP-31398, can induce apoptosis of human cancer cells and can stabilize wild-type p53 protein. Cancer Biol Ther 1:47-55.
40. Vogelstein B, Lane D, Levine AJ. 2000. Surfing the p53 network. Nature 408:307-310.
41. Volm M, Rittgen W. 2000. Cellular predictive factors for the drug response of lung cancer. Anticancer Res 20:3449-3458.
42. Weisz L, Zalcenstein A, Stambolsky P, Cohen Y, Goldfinger N, Oren M, Rotter V. 2004. Transactivation of the EGR1 gene contributes to mutant p53 gain of function. Cancer Res 64:8318-8327.
43. Yee KS, Vousden KH. 2005. Complicating the complexity of p53. Carcinogenesis 26:1317-1322.